Neel Vaidya, MD
Ophthalmology · Highland Park, ILNPI 1285098541
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 57.9% of the total. 2025 is the largest year on record at $82,861, more than ten times the $373 reported in 2019. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $440.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$90K
- Rxsight Inc$15K
- Dompe US, Inc.$10K
- Carl Zeiss Meditec, Inc.$10K
- Alcon$8K
- AbbVie$7K
- plus $14K from 18 others
Across 34 payments — averaging $2048.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$66K
- Glaukos Corporation$4K
What the payments were for
- Consulting fees$41,48227%
- Speaking & faculty fees$85,31455%
- Travel & lodging$14,5079%
- Food & beverage$14,95510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 95 | $90,417 |
| Rxsight Inc | 25 | $15,320 |
| Dompe US, Inc. | 30 | $10,493 |
| Carl Zeiss Meditec, Inc. | 18 | $10,108 |
| Alcon | 53 | $8,316 |
| AbbVie(2 entities) | 14 | $7,444 |
| Glaukos Corporation | 12 | $6,119 |
| Carl Zeiss Meditec USA, Inc. | 17 | $4,178 |
| Sun Pharmaceutical Industries Inc. | 23 | $1,425 |
| Novartis | 19 | $676 |
| Oyster Point Pharma, Inc. | 7 | $297 |
| Biotissue Holdings Inc. | 5 | $290 |
| Tarsus Pharmaceuticals, Inc. | 4 | $269 |
| Harrow Eye, LLC | 6 | $253 |
| Amgen(2 entities) | 9 | $201 |
| Mallinckrodt Hospital Products Inc. | 6 | $143 |
| Novo Nordisk | 1 | $112 |
| Lensar, Inc. | 2 | $47 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Beaver-visitec International, Inc. | 1 | $25 |
| Sight Sciences, Inc. | 1 | $23 |
| Aerie Pharmaceuticals, Inc. | 1 | $21 |
| NEW World Medical,inc. | 2 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$80,995
- MIEBO$80,777
- enVista MX60 IOL$15,966
- RXSIGHT CONTACT LENS$14,931
- RXSIGHT INJECTOR CARTRIDGE$14,931
- RXSIGHT INJECTOR HANDPIECE$14,931
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$14,931
- LIGHT ADJUSTABLE LENS (LAL)$14,822
- Oxervate$9,856
- enVista Aspire IOL$7,983
- ARTEVO 800$6,907
- Epioxa$4,125
- VisuMax$3,155
- MEL 90$1,750
- Travoprost Intraocular Implant - iDose$1,557
- FORUM$1,155
- CEQUA$842
- QUATERA 700$586
- LUMERA 700$468
- ATLAS 500$385
How this compares
$156,258 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 20 | $560,992 |
| XiidraLifitegrast | 32 | $40,651 |
| RestasisCyclosporine | 36 | $34,734 |
| Prednisolone Acetate | 348 | $16,225 |
| CequaCyclosporine | 14 | $11,071 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,467 |
| Brimonidine Tartrate | 74 | $7,265 |
| Ketorolac Tromethamine | 186 | $4,334 |
| Ofloxacin | 210 | $2,440 |
| Latanoprost | 175 | $2,142 |
| ValacyclovirValacyclovir Hcl | 21 | $1,512 |
| Fluorometholone | 16 | $1,177 |
| MoxifloxacinMoxifloxacin Hcl | 34 | $784 |
| ErythromycinErythromycin Base | 50 | $517 |
| Acyclovir | 12 | $384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $10,493 | $560,99220 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $90,417 | $51,11846 claims |
| AbbVieRestasis | $7,444 | $34,73436 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,425 | $11,07114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Highland Park
- Parag MajmudarHighland Park$451K
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.